290 related articles for article (PubMed ID: 16273263)
61. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide.
Soni S; Lee DS; DiVito J; Bui AH; DeRaffele G; Radel E; Kaufman HL
J Pediatr Hematol Oncol; 2002; 24(6):488-91. PubMed ID: 12218599
[TBL] [Abstract][Full Text] [Related]
62. [Live xenogenic vaccine in the prevention of metastases of uveal melanoma].
Brovkina AF; Keshelava VV; Sologub VK; Koromyslova IK; Severin SE; Barannikova TV
Vestn Oftalmol; 2009; 125(5):46-50. PubMed ID: 19916336
[TBL] [Abstract][Full Text] [Related]
63. Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma.
Herrington WG; Talbot DC; Lahn MM; Brandt JT; Callies S; Nagle R; Winearls CG; Roberts IS
Am J Kidney Dis; 2011 Feb; 57(2):300-3. PubMed ID: 21177011
[TBL] [Abstract][Full Text] [Related]
64. Treatment of metastatic uveal melanoma: review and recommendations.
Albert DM; Niffenegger AS; Willson JK
Surv Ophthalmol; 1992; 36(6):429-38. PubMed ID: 1589858
[TBL] [Abstract][Full Text] [Related]
65. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.
Peters S; Voelter V; Zografos L; Pampallona S; Popescu R; Gillet M; Bosshard W; Fiorentini G; Lotem M; Weitzen R; Keilholz U; Humblet Y; Piperno-Neumann S; Stupp R; Leyvraz S
Ann Oncol; 2006 Apr; 17(4):578-83. PubMed ID: 16469752
[TBL] [Abstract][Full Text] [Related]
66. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2).
von Hagens C; Walter-Sack I; Goeckenjan M; Storch-Hagenlocher B; Sertel S; Elsässer M; Remppis BA; Munzinger J; Edler L; Efferth T; Schneeweiss A; Strowitzki T
Phytomedicine; 2019 Feb; 54():140-148. PubMed ID: 30668363
[TBL] [Abstract][Full Text] [Related]
67. New therapeutic agents in uveal melanoma.
Velho TR; Kapiteijn E; Jager MJ
Anticancer Res; 2012 Jul; 32(7):2591-8. PubMed ID: 22753717
[TBL] [Abstract][Full Text] [Related]
68. The anti-malarial artesunate is also active against cancer.
Efferth T; Dunstan H; Sauerbrey A; Miyachi H; Chitambar CR
Int J Oncol; 2001 Apr; 18(4):767-73. PubMed ID: 11251172
[TBL] [Abstract][Full Text] [Related]
69. Autologous soluble tumor-associated antigens prevent the toxic side effects of cancer chemotherapy and inhibit the progress of tumorigenesis: case report.
Ben-Hur H; Zusman R; Zusman I
Oncol Rep; 2003; 10(6):2059-61. PubMed ID: 14534743
[TBL] [Abstract][Full Text] [Related]
70. [Therapy of metastatic malignant uveal melanoma].
Jäckel A; Bock M; Deichmann M; Waldmann V; Näher H
Hautarzt; 2001 Feb; 52(2):98-103. PubMed ID: 11244899
[TBL] [Abstract][Full Text] [Related]
71. Metastatic uveal melanoma.
Singh AD; Borden EC
Ophthalmol Clin North Am; 2005 Mar; 18(1):143-50, ix. PubMed ID: 15763199
[TBL] [Abstract][Full Text] [Related]
72. A motion for cautious optimism in the treatment of patients with ocular melanoma: the ayes have it.
Alexander HR
Ann Surg Oncol; 2005 Jun; 12(6):417-9. PubMed ID: 15886901
[No Abstract] [Full Text] [Related]
73. A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.
Itchins M; Ascierto PA; Menzies AM; Oatley M; Lo S; Douraghi-Zadeh D; Harrington T; Maher R; Grimaldi AM; Guminski A
Melanoma Res; 2017 Jun; 27(3):243-250. PubMed ID: 28230715
[TBL] [Abstract][Full Text] [Related]
74. A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.
Shoushtari AN; Ong LT; Schoder H; Singh-Kandah S; Abbate KT; Postow MA; Callahan MK; Wolchok J; Chapman PB; Panageas KS; Schwartz GK; Carvajal RD
Melanoma Res; 2016 Jun; 26(3):272-7. PubMed ID: 26795274
[TBL] [Abstract][Full Text] [Related]
75. Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature.
Efferth T; Schöttler U; Krishna S; Schmiedek P; Wenz F; Giordano FA
Arch Toxicol; 2017 Apr; 91(4):1833-1846. PubMed ID: 27519711
[TBL] [Abstract][Full Text] [Related]
76. Identification of novel chemotherapeutic strategies for metastatic uveal melanoma.
Fagone P; Caltabiano R; Russo A; Lupo G; Anfuso CD; Basile MS; Longo A; Nicoletti F; De Pasquale R; Libra M; Reibaldi M
Sci Rep; 2017 Mar; 7():44564. PubMed ID: 28303962
[TBL] [Abstract][Full Text] [Related]
77. Intravascular metastatic melanoma of the vena saphena magna.
Saint-Cyr I; Boisseau-Garsaud AM; Pont F; Cales-Quist D; Helenon R; Chinyavong T
Int J Dermatol; 2004 Aug; 43(8):590-2. PubMed ID: 15304184
[TBL] [Abstract][Full Text] [Related]
78. Fotemustine-dacarbazine combinations in the treatment of metastatic melanoma.
Merimsky O; Chaitchik S
Eur J Cancer; 1993; 29A(3):481-2. PubMed ID: 8398358
[No Abstract] [Full Text] [Related]
79. Screening for uveal melanoma metastasis. Literature review.
Missotten GS; Keunen JE
Bull Soc Belge Ophtalmol; 2004; (294):13-22. PubMed ID: 15682915
[TBL] [Abstract][Full Text] [Related]
80. [A case of metastatic uveal melanoma of the liver and digestive tract].
Hachiya M; Satoh K; Takami S; Uetake S; Arihiro S; Hokari A; Ishikawa T; Takagi I; Tajiri H; Saruta M
Nihon Shokakibyo Gakkai Zasshi; 2017; 114(11):1978-1986. PubMed ID: 29109346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
